Tumours in Cluster I are enriched in FGFR3 overexpression due to mutations and amplification and show better overall survival, whereas those in cluster II, designated “p53-like” tumours, express active p53 gene signatures and are resistant to neoadjuvant cisplatin-based combination chemotherapy [3]. Here, FGFR3 is linked to neoplasm.